Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Rheumatology Coding Corner Question: Billing for an Inflectra Infusion

  |  Issue: May 2018  |  

A 68-year-old female patient returns to the office for a second round of Inflectra (infliximab-dyyb) infusion for her rheumatoid arthritis with rheumatoid factor of multiple joints without organ or systems involvement. She reports pain, stiffness and swelling in her left and right knees and right elbow and rates the pain at a 9 on a 10-point scale. She currently takes an NSAID and methotrexate 15 mg once weekly. She has no known allergies and denies any other complaints.

Upon examination, her temperature is 98°F, weight is 135 lbs., and blood pressure is 110/75.

ADVERTISEMENT
SCROLL TO CONTINUE

The patient is given a premed push of 50 mg of diphenhydramine and then infused with 200 mg of infliximab-dyyb for a total of 1 hour 43 minutes. The patient’s medication is left unchanged.

Note: The infusion began at 11:05 a.m. and ended at 12:48 p.m.

ADVERTISEMENT
SCROLL TO CONTINUE

Click here for the answer(s).

Related Articles

    Possible Impact of Biosimilar Infliximab on U.S. Market in Prescriptions, Pricing

    The use of biosimilars for rheuma­tology in the U.S. became a reality when the U.S. Food and Drug Administration (FDA) approved Inflectra (infliximab-dyyb), a biosimilar to Remicade (infliximab), in April. What this may mean is increased competition among drug companies with regard to pricing and, therefore, potentially lower costs for U.S. patients, according to Seoyoung…

    Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis

    Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and small molecule inhibitor drugs…

    Medicalwriters/Science Source

    Biosimilars Are Slowly Climbing Toward Acceptance in Rheumatology

    As useful stand-ins for biologics targeting a range of inflammatory diseases, biosimilars have made significant inroads across Europe as less expensive alternatives. Denmark, for example, realized a cost savings of 64% after instituting a mandatory national switch from the originator infliximab to its biosimilar counterpart. In the U.S., however, a considerably smaller fraction of rheumatologists…

    Syda Productions/shutterstock.com

    Tips, Resources to Help Rheumatologists Educate Patients on Biologics and Biosimilars

    Rheumatologists are accustomed to educating patients about medications—but biologic medications require some additional time and discussion. “Biologics are inherently more complex [than other medications], and there are multiple issues to consider before initiating treatment,” says K. “Kwas” Huston, MD, The Center for Rheumatic Disease, Kansas City, Mo. “This includes the patient’s disease activity, prior medications…